SCHEMBL1367949

SCHEMBL1367949

COc1ccc2cc(C(=O)/C=C/c3ccc(Cl)cc3)c(=O)sc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 6/20 0.62
MAOB P27338 5/20 0.62
MAOA P21397 1/20 0.55
MAPT P10636 4/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
ALDH1A1 P00352 2/20 0.52
MEN1 O00255 2/20 0.51
MAPK1 P28482 2/20 0.51
KMT2A Q03164 2/20 0.51
LMNA P02545 1/20 0.51
APP P05067 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C19 P33261 1/20 0.51
TNFRSF1A P19438 1/20 0.51
PADI4 Q9UM07 1/20 0.49
KDM4E B2RXH2 1/20 0.49
HPGD P15428 1/20 0.49
ALOX15 P16050 1/20 0.49
HSD17B10 Q99714 1/20 0.49
TDP1 Q9NUW8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1367951 1.00 ABCG2 (0.62) ABCG2MAOBMAOAMAPTSMN1; SMN2
SCHEMBL1369587 1.00 ABCG2 (0.62) ABCG2MAOBMAOAMAPTSMN1; SMN2
SCHEMBL1368032 0.94 ABCG2 (0.57) ABCG2MAOBMAOAMAPTSMN1; SMN2
SCHEMBL1368033 0.94 ABCG2 (0.57) ABCG2MAOBMAOAMAPTSMN1; SMN2
SCHEMBL4344624 0.94 ABCG2 (0.57) ABCG2MAOBMAOAMAPTSMN1; SMN2
SCHEMBL1367940 0.88 ABCG2 (0.58) ABCG2MAOBMAOAMAPTSMN1; SMN2
SCHEMBL1367939 0.88 ABCG2 (0.58) ABCG2MAOBMAOAMAPTSMN1; SMN2
SCHEMBL1369244 0.88 ABCG2 (0.58) ABCG2MAOBMAOAMAPTSMN1; SMN2
SCHEMBL1369726 0.87 MAPT (0.51) ABCG2MAOBMAOAMAPTSMN1; SMN2
SCHEMBL1369254 0.87 MAPT (0.51) ABCG2MAOBMAOAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US claimed
WO-2006132947-A2 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-12-14 WO claimed
US-8067461-B2 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2011-11-29 US disclosed
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof NQO2, NQO1, HCCS ABCG2 57/4885MAOB 2929/4885MAOA 3570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.